Category / Industry news

eXmoor and Virica receive funding to improve AAV gene therapy manufacturing Partners will develop formulations of VSEs™ and validate their ability to improve yields of adeno-associated vector (AAVs) at scale, lowering gene therapy costs at commercial scale Virica and eXmoor will receive advisory services and funding through collaborative Canada-UK government program Bristol, UK and Ottawa,…

Quell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership with eXmoor pharma Multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies Partnership builds on long-term relationship to provide Quell with additional dedicated GMP capacity, infrastructure and resources at eXmoor’s new, state-of-the-art Cell & Gene Therapy…

eXmoor Pharma's GMP cell and gene therapy manufacturing facility receives license from MHRA eXmoor’s Cell & Gene Therapy Centre can now offer a full range of GMP services for cell and gene therapies including manufacture, fill/finish, packaging, labelling, and shipping to global clinical sites Bristol, UK, 20 August 2024 – eXmoor pharma, the full-service cell…

eXmoor appoints Matthew Paterson as first Chief Commercial Officer New CCO to apply experience growing US and UK business to support eXmoor's expansion Bristol, UK, November 16, 2023 – eXmoor pharma, the full-service cell and gene therapy (CGT) manufacturing partner, announced the hiring of Matthew Paterson as the company’s first Chief Commercial Officer, to spearhead the company’s…

eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May 30, 2023 – eXmoor pharma, the end-to-end cell and gene therapy (CGT) manufacturing partner, today announced the close of a…

eXmoor pharma and vaccine developer Imophoron sign process development partnership Multi-phase partnership will aim to manufacture vaccines for clinical use in eXmoor’s new facility to be launched in Q3, 2023 Bristol, UK, February 22, 2023 – eXmoor pharma, the cell and gene therapy partner specializing in accelerating the manufacturing journey from research to patients and…

eXmoor to present at OBN BioTuesday: 'A Spotlight on the Latest Research and Innovation In Cell & Gene Therapy' - 21 February eXmoor are delighted to participate in OBN's upcoming  BioTuesday event on 21 February, spotlighting 'Latest Research and Innovation In Cell & Gene Therapy'. During the evening, we will hear from some key thought…

eXmoor Pharma appoints CTO as part of ambitious expansion strategy Lucy Foley joins eXmoor after eight years at the Centre for Process Innovation (CPI) with her most recent position as Director of Biologics and COVID response. Bristol, 9th February 2022 - Bristol based, eXmoor Pharma is pleased to announce the appointment of Dr. Lucy Foley…

eXmoor Pharma secures contract to work with New Zealand Blood Service This will be eXmoor’s first project in the Australasia region. The UK-based delivery team has adapted its working processes to allow for collaborative communication across time zones with the NZBS team. 11 January 2021: eXmoor Pharma, experts in strategic and technical biomanufacturing, specialising in…